Association of Urine Albumin-Creatinine Ratio and Cystatin C-Based Estimated GFR with Outcomes in Patients with Ischemic Stroke

Yilun Zhou\textsuperscript{a} Yu Wu\textsuperscript{a} Yuesong Pan\textsuperscript{b,c} Hao Li\textsuperscript{b,c} Hongyi Yan\textsuperscript{b} Xia Meng\textsuperscript{b,c} Jinxi Lin\textsuperscript{b,c} Hong Wang\textsuperscript{d} Kunihiro Matsushita\textsuperscript{e} Yongjun Wang\textsuperscript{b,c}

\textsuperscript{a}Department of Nephrology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; \textsuperscript{b}China National Clinical Research Center for Neurological Diseases, Beijing, China; \textsuperscript{c}Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China; \textsuperscript{d}Center for Metabolic Disease Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; \textsuperscript{e}Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Keywords
Urine albumin-creatinine ratio · Cystatin C-based estimated GFR · Ischemic stroke

Abstract

\textbf{Background/Aims:} Data about the independent and combined effects of cystatin C-based estimated glomerular filtration rate (eGFR\textsubscript{cys}) and albuminuria on the risk of poor outcome in stroke patients are limited. The aim was to elucidate how these two renal markers affect the clinical outcomes after ischemic stroke separately and jointly. \textbf{Methods:} The study subjects consisted of 10,197 patients with ischemic stroke from the third China National Stroke Registry. The study outcomes were all-cause mortality, poststroke disability, recurrence of stroke, and cardio-cerebral vascular disease (CVD) composite events. Cox proportional hazard models and multivariable logistic regression model were applied to evaluate the effects of eGFR\textsubscript{cys} and urine albumin-creatinine ratio (ACR) on these outcomes. \textbf{Results:} Both reduced eGFR\textsubscript{cys} and increased ACR were independently associated with higher incidences of all-cause death and poststroke disability ($p < 0.01$). Mildly decreased eGFR\textsubscript{cys} (60–89 mL/min/1.73 m$^2$) is associated with increased risk of all-cause death and poststroke disability in the presence of high-normal ACR (10–29 mg/g). Patients with both eGFR\textsubscript{cys} <45 mL/min/1.73 m$^2$ and ACR ≥30 mg/g at baseline had a 6.8-fold risk for all-cause mortality and 3.6-fold risk for poststroke disability, compared with patients with eGFR\textsubscript{cys} of 90–119 mL/min/1.73 m$^2$ and ACR <10 mg/g. In addition, increased ACR was associated with recurrent stroke and CVD composite event, while reduced eGFR\textsubscript{cys} showed no relationship with these outcomes. \textbf{Conclusions:} Both decreased eGFR\textsubscript{cys} and albuminuria are independent risk factors for all-cause death and poststroke disability. Combining the two markers is useful for improving risk stratification even in those without chronic kidney disease.

Introduction

Emerging data suggest positive association between kidney damage manifested by increased albuminuria or decreased estimated glomerular filtration rate (eGFR) with cerebrovascular and cardiovascular disease in the

Yilun Zhou and Yu Wu contributed equally.
stroke patients [1–8] as well as general population [9–13]. As an alternative filtration marker, cystatin C-based eGFR (eGFRcys) has a stronger association with mortality and cardiovascular disease than does eGFR based on creatinine (eGFRcr) and improves risk stratification [14–16]. However, studies investigating the prognostic roles of albuminuria for adverse clinical outcomes among post-stroke patients are mostly small-sample sized and short-term followed, and the predictive value of eGFRcys for stroke outcome remains unclear [17, 18]. Furthermore, no studies have evaluated the independent and combined effects of eGFRcys and albuminuria on the risk of poor stroke outcome in a large prospective stroke cohort.

The purpose of the present study is to describe the effect of decreased eGFRcys and increased urine albumin-creatinine ratio (ACR) alone and in combination of both on the all-cause mortality, poststroke disability, recurrence of stroke, and cardiocerebral vascular disease (CVD) composite events in patients with ischemic stroke. Meanwhile, since prior studies suggest that even minor anomaly in eGFR and urine ACR predict vascular risks [11, 19], there is a need to explore the combined association of these markers in categories that are lower than the current clinical cutoffs for defining chronic kidney disease (CKD).

Methods

Study Population

Our source population included participants from the third China National Stroke Registry (CNSR-III), a nationwide clinical registry of ischemic stroke or TIA in China. In the CNSR-III cohort, 15,166 patients were enrolled between August 2015 and March 2018. Details of the CNSR-III cohort are described elsewhere [20]. In the present study, we included participants who had serum cystatin C and urinary ACR centrally measured, and with 1-year follow-up data from CNSR-III. The baseline data of included patients was collected within 24 h after admission through a face-to-face interview by research coordinators. Medical history included a history of diabetes, hypertension, and coronary heart disease, and atrial fibrillation. Baseline information included age, sex, and body mass index. Stroke severity was assessed by the National Institute of Health Stroke Scale (NIHSS) and disability was assessed by the modified Rankin Scale (mRS) within 24 h of admission.

Measurements

Blood and urine samples were collected by the first day of enrolment (within 24 h). All the blood and urine samples were frozen in cryotube at −80°C refrigerator. The samples were transported through cold chain to the centre laboratory in Beijing Tiantan Hospital, where all serum and urine specimens were stored at −80°C until testing was performed. The value of serum cystatin C was measured by the immunoturbidimetric method (Roche cobas c501 analyzer with cystatin C assay), which has an approximate coefficient of variation of 2%. The values of eGFRcys were calculated using the equations from the Chronic Kidney Disease Epidemiology Collaboration [16]. Participants were categorized into 5 eGFRcys categories: ≥120, 90–119, 60–89, 45–59, and <45 mL/min/1.73 m². Urine ACR was estimated in mg albumin/g creatinine (mg/g). Participants were categorized into 3 categories based on urine ACR level: optimal (<10 mg/g), high-normal (10–29 mg/g), and albuminuria (≥30 mg/g). Study technicians running the assays were blinded to the participant’s clinical information.

Outcome Assessment

Clinical outcomes included all-cause death, stroke recurrence, and CVD composite event which occurred during 1-year, and poststroke disability at 1-year. Death was confirmed either by the death certificates from the attended hospital or the local citizen registry. Poststroke disability was defined by scores on the mRS range from 3 to 6. Stroke recurrence included ischemic stroke and haemorrhagic stroke. CVD composite event included ischemic stroke, haemorrhagic stroke, myocardial infarction, or vascular death.

Statistical Analysis

eGFR of 90–119 mL/min/1.73 m² and ACR <10 mg/g were used as the reference category. Continuous variables between groups were compared using ANOVA test, or Mann-Whitney U test; categorical variables were compared using χ² test. Cox proportional hazard models were used to estimate hazard ratios (HRs) for all-cause mortality, recurrence of stroke, and CVD composite events. Multivariable logistic regression model was used for assessment of variables that were associated with poststroke disability by calculating odds ratio (OR) and 95% CI. Models were adjusted for clinically potential relevant covariates including age, sex, hypertension, diabetes, coronary heart disease, atrial fibrillation, current smoking, total cholesterol level, NIHSS score, and mRS on admission. Interaction between eGFRcys and ACR was assessed using ACR as a categorical variable, using likelihood ratio test to compare models.

Results

General Characteristics of all Participants

Of the 15,166 patients with ischemic stroke or TIA consecutively enrolled in the CNSR-III, 3,905 (25.7%) participants from 30 study sites did not participate the biomarker study; in addition, 768 patients were excluded for lack of ACR and 296 for lack of serum cystatin C data at baseline. Eventually, 10,197 patients were included in the study, including 6,990 men and 3,207 women. There were 274 (2.7%), 3,350 (32.9%), 4,778 (46.9%), 1,222 (12.0%), and 573 (5.6%) patients classified into eGFRcys ≥120, 90–119, 60–89, 45–59, and <44 mL/min/1.73 m², respectively. Meanwhile, 5,871 (57.6%), 1,892 (18.6%), and 2,434 (23.9%) patients were classified into ACR groups <10, 10–29, ≥30 mg/g, respectively. Baseline char-
acteristic data in five eGFR<sub>cys</sub> categories and three ACR categories are listed in Table 1. Compared with patients with higher eGFR<sub>cys</sub> or lower ACR, those with lower eGFR<sub>cys</sub> or higher ACRs were likely to be older; have lower proportion of male; a higher prevalence of current smokers, diabetes, hypertension, atrial fibrillation, coronary heart disease; a higher mean total cholesterol, creatinine, cystatin C, NIHSS score, and mRS on admission. While patients with eGFR ≥120 mL/min/1.73 m<sup>2</sup> were likely to be younger, male, have higher BMI, and higher prevalence of diabetes compared with those with eGFR 90–119 mL/min/1.73 m<sup>2</sup>. Table 2 shows the proportions of patients in each eGFR<sub>cys</sub> and urine ACR category. The majority of participants had urine ACR <10 mg/g except those with eGFR<sub>cys</sub> <45 mL/min/1.73 m<sup>2</sup>. For those with eGFR<sub>cys</sub> of <120 mL/min/1.73 m<sup>2</sup>, a stepwise increase in the prevalence of ACR ≥30 mg/g was identified as eGFR decreased.

**Outcomes**

**Crude Incidence Rates**

Table 3 shows unadjusted incidence rates for all the four outcomes. A total of 323 (3.17%) deaths, 1,283 (12.58%) poststroke disability events, 1,004 (9.84%) stroke recurrence, and 1,059 (10.39%) CVD events occurred during a median follow-up of 1 year. Incidence rates for all events were higher in those in the lower baseline eGFR<sub>cys</sub> categories or those with higher ACR. The 1-year cumulative incidence of all-cause death in patients with an eGFR ≥120, 90–119, 60–89, 45–59, and <45 mL/min/1.73 m<sup>2</sup> were 2.19, 1.34, 2.99, 6.06, and 9.60%, respectively. Those of poststroke disability were 9.7, 9.0, 12.5, 20.2, and 25.9%, respectively.

When participants were classified by urine ACR at baseline, the 1-year cumulative incidences of all-cause death with ACR <10, 10–29, ≥30 mg/g were 1.77, 2.59, and 6.98%, respectively, while those of poststroke disability were 8.57, 13.32, and 23.09%, respectively. Substantially higher incidence rates were observed across ACR categories within the same eGFR<sub>cys</sub> category. For example, in the eGFR<sub>cys</sub> category of 60–89 mL/min/1.73 m<sup>2</sup>, the incidence rate of all-cause mortality was nearly 3.7 fold as high for those with ACR of ≥30 mg/g (6.63%) compared with those with ACR <10 mg/g (1.79%) (Table 4).

**Independent Associations of eGFR<sub>cys</sub> and ACR with Outcome**

As shown in Table 3 and Figure 1, eGFR<sub>cys</sub> did not suggest the risk of recurrent stroke and CVD composite event. However, reduced eGFR<sub>cys</sub> was a significant risk
Table 1. Baseline characteristics stratified by eGFRcys and ACR

| eGFRcys, mL/min/1.73m² | ACR, mg/g | Overall |
|------------------------|-----------|---------|
|                        | <10       | 10–29   | ≥30     |
| ≥120                   | 159 (58.03) | 54 (19.71) | 61 (22.26) | 274 (2.69) |
| 90–119                 | 2,077 (62.00) | 636 (18.99) | 637 (19.01) | 3,350 (32.89) |
| 60–89                  | 2,902 (60.74) | 866 (18.12) | 1,010 (21.14) | 4,778 (46.90) |
| 45–59                  | 566 (46.32) | 260 (21.28) | 396 (32.41) | 1,222 (12.00) |
| <45                    | 167 (29.14) | 76 (13.26) | 330 (57.59) | 573 (5.62) |
| Overall                | 5,871 (57.58) | 1,891 (18.55) | 2,434 (23.87) | 10,197 |

ACR, albumin-creatinine ratio; eGFRcys, cystatin C-based estimated glomerular filtration.

Table 2. Prevalence of ACR in each category of eGFRcys

| eGFRcys, mL/min/1.73m² | ACR, mg/g | Overall |
|------------------------|-----------|---------|
|                        | <10       | 10–29   | ≥30     |
| ≥120                   | 159 (58.03) | 54 (19.71) | 61 (22.26) | 274 (2.69) |
| 90–119                 | 2,077 (62.00) | 636 (18.99) | 637 (19.01) | 3,350 (32.89) |
| 60–89                  | 2,902 (60.74) | 866 (18.12) | 1,010 (21.14) | 4,778 (46.90) |
| 45–59                  | 566 (46.32) | 260 (21.28) | 396 (32.41) | 1,222 (12.00) |
| <45                    | 167 (29.14) | 76 (13.26) | 330 (57.59) | 573 (5.62) |
| Overall                | 5,871 (57.58) | 1,891 (18.55) | 2,434 (23.87) | 10,197 |

ACR, albumin-creatinine ratio; eGFRcys, cystatin C-based estimated glomerular filtration.

Fig. 1. HRs with 95% confidence intervals of eGFRcys with the all-cause mortality (a), recurrence of stroke (c), CVD composite events (d), and ORs with 95% confidence intervals of eGFRcys with the poststroke disability (b). Reference group is eGFRcys of 90–119 mL/min/1.73 m².
factor for all-cause death and poststroke disability. Compared with the reference eGFR$_{\text{cys}}$ of 90–119 mL/min, the HRs for all-cause mortality were 1.56 in those with eGFR$_{\text{cys}}$ of 60–89 mL/min (95% CI: 1.10–2.21), 2.23 in those with eGFR$_{\text{cys}}$ of 45–59 mL/min (95% CI: 1.49–3.35), and 3.25 in those with eGFR$_{\text{cys}}$ of <45 mL/min (95% CI: 2.11–5.00). The ORs for stroke disability was 1.42 (95% CI: 1.14–1.78) for those with eGFR$_{\text{cys}}$ of 45–59 mL/min/1.73 m$^2$, and 1.9 (95% CI: 1.46–2.49) for those with eGFR$_{\text{cys}}$ of <45 mL/min/1.73 m$^2$.

As shown in Table 3 and Figure 2, compared to patients with ACR <10 mg/g, risks for CVD composite event (HR 1.19; 95% CI, 1.01–1.40) and poststroke disability (OR 1.35; 95% CI: 1.13–1.61) in patients with ACR 10–29 mg/g were significantly higher, while ACR ≥30 mg/g were associated with increase in risk of all these four poor outcomes. The relationship of ACR to the relative risk of the adverse outcomes was monotonic with HRs or ORs increasing linearly with increasing ACR, without threshold effects.

### Combined Associations of eGFR and ACR with All-Cause Mortality and Poststroke Disability

HRs and ORs were calculated in fifteen subgroups classified according to eGFR$_{\text{cys}}$ and category of urine ACR to determine the joint effect of these renal biomarkers on the risk of all-cause mortality and poststroke disability. As shown in Table 4, in the ACR category of <10 mg/g, HRs were 3.34 (95% CI: 1.73–6.45) and 3.41 (95% CI: 1.45–7.98) in those with eGFR$_{\text{cys}}$ of 45–59 and <45 mL/min/1.73 m$^2$, respectively, for the all-cause mortality. In the ACR category of ≥30 mg/g, HRs for all-cause mortality were 9.00 (95% CI: 2.96–27.43) for those with eGFR$_{\text{cys}}$ of ≥120 mL/min/1.73 m$^2$, and for those with eGFR$_{\text{cys}}$ of <120 mL/min/1.73 m$^2$, a stepwise increase in the HRs was identified as eGFR decreased. When the results were analyzed according to the stage of eGFR$_{\text{cys}}$, the risk for all-cause mortality generally increased as urinary ACR rised. Patients with both eGFR$_{\text{cys}}$ <45 mL/min/1.73 m$^2$ and ACR ≥30 mg/g at baseline had a 6.8-fold higher risk for all-cause mortality, compared with the reference group. The interaction p value for ACR and eGFR$_{\text{cys}}$ with all-cause mortality was 0.095.

When compared with the reference group, in the ACR 10–29 mg/g categories, risks for poststroke disability were 1.81 (95% CI: 1.36–2.41) and 2.11 (95% CI: 1.13–3.92) in patients with eGFR$_{\text{cys}}$ 60–89 and <45 mL/min/1.73 m$^2$, respectively. While the ORs significantly increased in all eGFR$_{\text{cys}}$ categories when ACR was ≥30 mg/g. Patients with both eGFR$_{\text{cys}}$ <45 mL/min/1.73 m$^2$ and ACR ≥30 mg/g at baseline had a more than 3-fold risk for post-

### Table 3. Adjusted HRs or ORs of outcomes stratified by eGFR$_{\text{cys}}$ or ACR categories alone

| eGFR$_{\text{cys}}$, mL/min/1.73m$^2$ | All-cause death | Poststroke disability | Recurrent stroke | CVD composite event |
|--------------------------------------|-----------------|----------------------|-----------------|---------------------|
| ≥120                                 |                 |                      |                 |                     |
| 90–119                               |                 |                      |                 |                     |
| 60–89                                |                 |                      |                 |                     |
| 45–59                                |                 |                      |                 |                     |
| <45                                  |                 |                      |                 |                     |
| ACR, mg/g                            |                 |                      |                 |                     |
| <10                                  |                 |                      |                 |                     |
| 10–29                                |                 |                      |                 |                     |
| ≥30                                  |                 |                      |                 |                     |

All HRs and ORs adjusted for age, sex, hypertension, diabetes, coronary heart disease, atrial fibrillation, current smoking, total cholesterol level, NIHSS score, mRS on admission, ACR, albuminuria, and eGFR$_{\text{cys}}$ category. ACR, albumin-creatinine ratio; eGFR$_{\text{cys}}$, cystatin C-based estimated glomerular filtration.
stroke disability compared with the reference group. The interaction p value for eGFRcys and ACR with poststroke disability event was not significant.

Combined Associations of eGFRcys and ACR with Recurrent Stroke and CVD Composite Event

We also estimated the combined effects of baseline eGFRcys and urine ACR on the risk for recurrent stroke and CVD events. As shown in Table 4, only in the category of ACR ≥30 mg/g, risks of recurrent stroke in those with eGFRcys 60–119 mL/min/1.73 m² were higher compared with reference group of eGFRcys 90–119 mL/min/1.73 m² and ACR <10 mg/g. Similarly, HRs for CVD composite event were significantly increased in all eGFRcys category except for eGFRcys of ≥120 mL/min/1.73 m² with an ACR ≥30 mg/g. The interaction p value for ACR and eGFRcys with recurrent stroke and CVD composite event was 0.998 and 0.980, respectively.

Discussion

This is the first large study to explore the independent and combined effect of eGFRcys and albuminuria in the post-acute ischemic stroke population. There are two main findings in the present study. Firstly, both reduced eGFRcys and increased ACR were associated with higher risk of all-cause death and poststroke disability independently from each other and traditional cerebrovascular risk factors. Secondly, risks for all-cause mortality and poststroke disability increased in patients with both elevated albuminuria and reduced eGFRcys, even at levels not reach the current cutoff of CKD, and the risks were at the highest in those with markedly elevated albuminuria and reduced eGFRcys.

Previous reports evaluating the relationship between eGFRcys and clinical outcomes after acute ischemic stroke have yielded conflicting results. Two small-scale studies

**Table 4. Adjusted HRs or ORs of outcomes stratified by combination of eGFRcys and ACR categories**

| eGFRcys, mL/min/1.73m² | ACR, mg/g | Primary endpoint |
|------------------------|-----------|-----------------|
| <10                    | 10–29     | ≥30             |
| All-cause death        | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) |
| ≥120 2/159 (1.26)      | 2.07 (0.47–9.08) | 0/54 (0) | 0 | 4/61 (6.56) | 9.00 (2.96–27.43) |
| 90–119 15/2,077 (0.72) | 1.0 (reference) | 6/636 (0.94) | 1.07 (0.42–2.76) | 24/637 (3.77) | 3.85 (2.02–7.37) |
| 60–89 52/2,902 (1.79) | 1.77 (0.99–3.17) | 24/866 (2.77) | 2.31 (1.20–4.46) | 67/1,010 (6.63) | 4.81 (2.70–8.56) |
| 45–59 26/566 (4.59)  | 3.34 (1.73–6.5) | 12/260 (4.62) | 2.76 (1.26–6.05) | 36/396 (9.09) | 5.14 (2.73–9.7) |
| <45 9/167 (5.39)       | 3.41 (1.45–7.98) | 7/76 (9.21) | 5.51 (2.20–13.84) | 39/330 (11.82) | 6.81 (3.64–12.75) |
| Poststroke disability  | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) |
| ≥120 10/155 (6.45)     | 1.17 (0.56–2.41) | 4/53 (7.55) | 1.11 (0.36–3.41) | 12/60 (20) | 2.66 (1.24–5.69) |
| 90–119 127/2,034 (6.24)| 1.0 (reference) | 54/621 (8.7) | 1.16 (0.811.65) | 114/625 (18.24) | 2.41 (1.79–3.24) |
| 60–89 244/2,836 (8.6) | 1.10 (0.86–1.39) | 128/838 (15.27) | 1.81 (1.36–2.41) | 209/981 (21.3) | 2.17 (1.67–2.83) |
| 45–59 88/553 (15.91)  | 1.62 (1.18–2.24) | 42/253 (16.6) | 1.42 (0.94–2.16) | 109/380 (28.68) | 2.67 (1.93–3.71) |
| <45 23/163 (14.11)    | 1.21 (0.72–2.02) | 17/75 (22.67) | 2.11 (1.13–3.92) | 102/319 (31.97) | 3.64 (2.59–5.10) |
| Recurrent stroke       | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) |
| ≥120 11/159 (6.92)    | 0.92 (0.50–1.71) | 3/54 (5.56) | 0.70 (0.22–2.18) | 7/61 (11.48) | 1.43 (0.67–3.05) |
| 90–119 163/2,077 (7.85)| 1.0 (reference) | 56/636 (8.81) | 1.08 (0.80–1.46) | 85/637 (13.34) | 1.63 (1.25–2.12) |
| 60–89 252/2,902 (8.68)| 1.02 (0.84–1.25) | 94/866 (10.85) | 1.24 (0.95–1.61) | 140/1,010 (13.86) | 1.56 (1.23–1.97) |
| 45–59 47/566 (8.3)   | 0.90 (0.64–1.26) | 31/260 (11.92) | 1.23 (0.83–1.84) | 51/396 (12.88) | 1.36 (0.98–1.89) |
| <45 13/167 (7.78)     | 0.81 (0.45–1.43) | 8/76 (10.53) | 1.08 (0.53–2.22) | 43/330 (13.03) | 1.38 (0.97–1.95) |
| CVD composite event   | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) | event rate, n (%) | HR (OR) (95% CI) |
| ≥120 12/159 (7.55)    | 1.00 (0.55–1.79) | 5/54 (9.26) | 1.14 (0.47–2.79) | 7/61 (11.48) | 1.41 (0.66–3.00) |
| 90–119 167/2,077 (8.04)| 1.00 (reference) | 56/636 (8.81) | 1.05 (0.78–1.43) | 90/637 (14.13) | 1.68 (1.30–2.18) |
| 60–89 264/2,902 (9.1) | 1.04 (0.85–1.27) | 101/866 (11.66) | 1.29 (1.00–1.66) | 148/1,010 (14.65) | 1.60 (1.27–2.01) |
| 45–59 50/566 (8.83)  | 0.92 (0.66–1.27) | 32/260 (12.31) | 1.22 (0.82–1.80) | 55/396 (13.89) | 1.40 (1.02–1.93) |
| <45 16/167 (9.58)     | 0.95 (0.56–1.60) | 10/76 (13.16) | 1.28 (0.67–2.45) | 46/330 (13.94) | 1.41 (1.00–1.98) |

All HRs and ORs adjusted for age, sex, hypertension, diabetes, coronary heart disease, atrial fibrillation, current smoking, total cholesterol level, NIHSS score, and mRS on admission. ACR, albumin-creatinine ratio; eGFRcys, cystatin C-based estimated glomerular filtration; CVD, cardiocerebral vascular disease.
demonstrated that albuminuria, but not eGFR, was significantly associated with major vascular events, disability or mortality after stroke [1, 2]. In contrast, two large-scale studies demonstrated that low eGFR was significantly associated with in-hospital death and at-discharge death/disability, but without the albuminuria adjusted in the multivariate model [6, 7]. Estimates of eGFR<sub>cr</sub> are routinely used; however, they may potentially lead to the overdiagnosis of CKD. Cystatin C is considered to be a potential alternative to serum creatinine for estimating GFR. In studies of prognosis, it has been consistently shown to be a better marker than creatinine, and eGFR<sub>cys</sub> could be used as a confirmatory test for an adverse prognosis in patients with CKD [16, 21]. In the present study, we observed significant correlation between eGFR<sub>cys</sub> and poor outcomes after additional adjustment for albuminuria. It should be noted that all the above studies were focused on in-hospital poor outcomes, but our study was followed up for 1 year. In addition, our previous work based on CNSR-III showed that, compared with eGFR based on formulas calculated by the measurement of either creatinine (eGFR<sub>cr</sub>), or creatinine in combination with cystatin C (eGFR<sub>com</sub>), eGFR<sub>cys</sub> may identify more patients at high risk of adverse outcomes after stroke/TIA (unpublished data). Therefore, in the present study, we selected cystatin C as the renal filtration marker to further classify the population into five renal function groups.

**Fig. 2.** HRs with 95% confidence intervals of urine ACR with the all-cause mortality (a), recurrence of stroke (c), CVD composite events (d), and ORs with 95% confidence intervals of ACR with the poststroke disability (b). Reference group is ACR <10 mg/g.
In the present study, 23.9% of the participants had ACR ≥30 mg/g while 17.6% had eGFR<sub>cys</sub> < 60 mL/min/1.73 m<sup>2</sup>. Furthermore, ACR have more effect than eGFR<sub>cys</sub> on the poor outcomes including recurrent stroke and CVD composite event. It has been postulated that albuminuria and reduced renal filtration function may contribute to poor prognosis of stroke through different pathophysiological mechanisms [1]. Reduced GFR is suggested to represent the renal manifestations of systemic atherosclerosis [22, 23], whereas albuminuria may indicate a generalized systemic vasculopathy [24, 25] and endothelial dysfunction [26, 27]. However, the risks for all-cause death and stroke disability increased multiplicatively when the two biomarkers of renal function were combined, even when both markers were mildly abnormal with eGFR<sub>cys</sub> of 60–89 mL/min/1.73 m<sup>2</sup> and ACR of 10–29 mg/g. In addition, although eGFR<sub>cys</sub> ≥120 mL/min/1.73 m<sup>2</sup> alone was not associated with any adverse outcomes, higher risks of all-cause death and poststroke disability were observed in the subgroup with both ACR ≥30 mg/g and eGFR<sub>cys</sub> ≥120 mL/min/1.73 m<sup>2</sup>. The hypothesized mechanism is hyperfiltration due to diabetes and higher BMI, but exact mechanism remains unclear and further investigation is needed in the future. Nonetheless, combined detection of these two markers may have more advantage in clinical practice.

In the present study, the majority of patients enrolled had ACR < 10 mg/g, and thus participants were categorized into 3 categories based on ACR level: <10, 10–29, and ≥30 mg/g. The high-normal urine ACR level of 10–29 mg/g, lower than current definitions of albuminuria of 30 mg/g recommended by the KDIGO clinical practice guideline [28], was associated with a 19% and 16% higher risk of CVD composite event and poststroke disability compared to the referent group of ACR <10 mg/g. Consistent with our results, albuminuria at levels of 10–29 mg/g is associated with greater risk of cardiovascular events, deaths, and heart failure in general population [11, 12, 29]. However, the level of albuminuria in previous studies evaluating relationship between ACR and stroke outcome is higher than 30 mg/g [1–5]. Therefore, there is a need to place more resources in the screening and intervention of high-normal albuminuria among the stroke population.

The strengths of this study include the large scale and prospective population-based cohort and the central laboratory assay of serum cystatin C and urine ACR. Furthermore, multiple other vascular risk factors were well characterized, which allow for assessment of the independent relationship between the two renal bio-markers and poor outcome. On the other hand, some limitations in the present study were identified. Firstly, the number of patients with severe renal impairment (eGFR < 60 mL/min/1.73 m<sup>2</sup> or ACR > 30 mg/g) was relatively small. Secondly, baseline serum cystatin C and urine ACR were measured only once. The day-to-day variability of ACR within individuals is high, such that a single sample may not accurately characterize the true level of albumin excretion. However, the large sample size and the central laboratory assay of serum cystatin C and urine ACR were the strengths of our study, thus the variance may be attenuated. In the future, multiple measurements of these markers are needed to reduce variability. Thirdly, subjects with absence of urine ACR or serum cystatin C data were not included in this study. The excluded patients were those with higher mRS on admission (1.94 ± 1.38 vs 1.89 ± 1.40, \(p = 0.03\)), the selection bias may not be excluded (online supplemental; see www.karger.com/doi/10.1159/000522140 for all online suppl. material).

In conclusion, we found a significant association between urinary albumin excretion combined with diminished eGFRcys at baseline and subsequent all-cause mortality and poststroke disability in patients with acute ischemic stroke. In the future, larger studies with multiple measurements of eGFR<sub>cys</sub> and ACR are needed to verify these renal markers for risk assessment in stroke patients.

**Statement of Ethics**

The protocol of the CNSR-III study was approved by the Ethics Committee at Beijing Tiantan Hospital (IRB approval number: KY2015-001-01) and all participating centres. Written informed consent was signed by patients or their legally authorized representatives.

**Conflict of Interest Statement**

The authors have no conflicts of interest to declare.

**Funding Sources**

This study was supported by grants from the Ministry of Science and Technology of the People’s Republic of China (2016YFC0901001, 2016YFC0901002, 2017YFC1310901, 2017YFC1310902, 2018YFC1311700, and 2018YFC1311706), and grants from the Beijing Municipal Commission of Health and Family Planning (No.2016-1-2041, SML20150502).
Author Contributions

Yongjun Wang had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Yongjun Wang, Yilun Zhou, and Yu Wu. Supplying patients: Xia Meng and Jinxi Lin. Drafting of the manuscript: Yilun Zhou and Yu Wu. Critical revision of the manuscript for important intellectual content: Yongjun Wang and Yilun Zhou. Statistical analysis: Yuesong Pan, Hao Li, and Hongyi Yan. Study supervision and organisation of the project: Yongjun Wang, Xia Meng, Jinxi Lin, Hong Wang, and Kunihiro Matsushita.

Data Availability Statement

The data that support the findings of this study are openly available in at http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Huang YC, Wu YL, Lee MH, Lee JD, Wu CY, Hsu HL, et al. Association of renal biomarkers with 3-month and 1-year outcomes among critically ill acute stroke patients. PLoS One. 2013;8:e72971.
2. Lee SJ, Song YL. Relationship between kidney dysfunction and ischemic stroke outcomes: albuminuria, but not estimated glomerular filtration rate, is associated with the risk of further vascular events and mortality after stroke. PLoS One. 2016;11:e0155939.
3. Kanamaru TS, Suda S, Muraga K, Okubo S, Watanabe Y, Tsuruoka S, et al. Albuminuria predicts early neurological deterioration in patients with acute ischemic stroke. J Neurol Sci. 2017;372:417–20.
4. Umemura T, Senda J, Fukami Y, Mashita S, Kawamura T, Sakakibara T, et al. Impact of albuminuria on early neurological deterioration and lesion volume expansion in lenticulostriate small infarcts. stroke. 2014;45:587–90.
5. Watanabe Y, Suda S, Kanamaru T, Katsumata T, Okubo S, Kaneko T, et al. High urinary albumin/creatinine ratio at admission predicts poor functional outcome in patients with acute ischaemic stroke. Nephrology. 2017;22:199–204.
6. El Hussein N, Forarow GC, Smith EE, Ju C, Schwamm LH, Hernandez AF, et al. Renal dysfunction is associated with poststroke discharge disposition and in-hospital mortality findings from get with the guidelines: stroke. Stroke. 2017;48:327–34.
7. Widhi Nugroho A, Arima H, Miyazawa I, Fujii T, Miyamatsu N, Sugimoto Y, et al. The association between glomerular filtration rate estimated on admission and acute stroke outcome: the shiga stroke registry. J Atheroscler Thromb. 2018;25:570–9.
8. Wang IK, Liu CH, Yen TH, Jeng JS, Sung SF, Huang PH, et al. Renal function is associated with 1-month and 1-year mortality in patients with ischemic stroke. Atherosclerosis. 2018;269:288–93.
9. Horn JW, Romundstad S, Ellekjær H, Janszky I, Horn J. Low grade albuminuria as a risk factor for subtype of strokes – the HUNT Study in Norway. BMC Neurol. 2020;20:170.
10. Lee M, Saver JL, Chang KH, Ovbiagele B. Level of albuminuria and risk of stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2010;30:464–9.
11. Chronic Kidney Disease Prognosis Consortium; Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular disease in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.
12. Blecker S, Matsushita K, Kottgen A, Loehr LR, Bertoni AG, Boulware LE, et al. High-normal albuminuria and risk of heart failure in the community. Am J Kidney Dis. 2011;58:47–55.
13. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18:1307–15.
14. Shilpak MG, Matsushita K, Årnlöv J, Inker LA, Katz R, Polkinghorne KR, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013;369:932–43.
15. Mooney JF, Croul BL, Cassidy S, Lee VW, Chow CK, Cuthbertson BH, et al. Relative value of cystatin C and creatinine-based esti-mates of glomerular filtration rate in predicting long-term mortality after cardiac surgery: a cohort study. BMJ Open. 2019;9:e029379.
16. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.
17. Hojs Fabjan T, Penko M, Hojs R. Cystatin C, creatinine, estimated glomerular filtration, and long-term mortality in stroke patients. Ren Fail. 2014;36:81–6.
18. Hojs Fabjan T, Penko M, Hojs R. Newer glomerular filtration rate estimating equations for the full age spectrum based on serum creatinine and cystatin C in predicting mortality in patients with ischemic stroke. Eur J Intern Med. 2018;52:67–72.
19. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJ, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73.
20. Wang Y, Jing J, Meng X, Pan Y, Wang Y, Zhao X, et al. The Third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics. Stroke Vasc Neurol. 2019;4:158–64.
21. Pitt-Rivers CA, Shilpak MG, Judd S, Cushman M, McClellan W, Zakai NA, et al. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumi-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA. 2011;305:1545–52.
22. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens. 1995;9:827–33.
23. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int Suppl. 1991;31:S29–34.
24. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Cufelton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardio-vascular disease: a statement from the American Heart Association Councils on kid-ney in cardiovascular disease, high blood pressure research, clinical cardiology, and ep-iemiology and prevention. Hypertension. 2003;42:1050–65.
25. Manjunath G, Tighiouart H, Coresh J, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovas-cular outcomes in the elderly. Kidney Int. 2003;63:1121–9.
26. Stehouwer CD, Smulders YM. Microalbumi-nuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17:2106–13.
27. Jefferson JA, Shankland SJ, Pichler RH. Pro-teinuria in diabetic kidney disease: a mecha-nistic viewpoint. Kidney Int. 2008;74:22–36.
28. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and managementof chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
29. Tanaka F, Komi R, Makita S, Onoda T, Tanno K, Ohsawa M, et al. Low-grade albuminuria and incidence of cardiovascular disease and end-stage renal mortality in nondiabetic and non-motivative individuals. J Hypertens. 2016;34:506–12; discussion 512.